阿托伐他汀治疗糖耐量减低原发性高血压的临床研究
|
摘要
目的研究阿托伐他汀治疗原发性高血压(EH)伴糖耐量减低(IGT)的临床效果。方法选取医院确诊且治疗的EH合并IGT患者90例,随机分为观察组(45例,常规降压治疗联合阿托伐他汀治疗)和对照组(45例,常规降压治疗),对比两组血压、血糖、血脂及血清炎症因子水平变化。结果治疗后两组的血压(SBP、DBP)均明显降低(P<0.05),但组间比较无统计学差异(P>0.05);治疗后观察组的血脂(LDL-C、TC、TG)、血糖(2h PG)、胰岛素抵抗指数(HOMA-IR)、血清炎症因子(IL-6、TNF-α)水平均明显低于对照组(P<0.05)。结论阿托伐他汀辅助治疗EH伴IGT能够有效减轻炎症反应,下调炎症因子,降低血糖、血脂及胰岛素抵抗,值得推广应用。
Objective To study the efficacy of atorvastatin on the treatment of EH complicated with IGT. Methods A total of90 patients with EH complicated with IGT diagnosed and treated in our hospital were selected and randomly divided into the observation group(n=45, treated with conventional antihypertensive therapy combined with atorvastatin therapy) and the control group(n =45, treated with conventional antihypertensive therapy). The changes in the blood pressure, blood glucose, and blood lipid and serum inflammatory factors in the two groups were compared. Results The blood pressure(SBP and DBP) in the two groups after the treatment dropped greatly(P < 0.05), but there is no statistical difference between groups(P > 0.05); the levels of blood fat(LDL-C, TC and TG), blood glucose(2h PG), insulin resistance index(HOMA-IR) and serum inflammatory factors(IL-6 and TNF-α) in the treatment group after the treatment were much lower than those in the control group(P < 0.05). Conclusion The adjunctive treatment with atorvastatin of EH complicated with IGT can effectively relieve inflammation, lower inflammatory factors, lower blood sugar, blood fat and insulin resistance, and is worthy of popularization and application.
Objective To study the efficacy of atorvastatin on the treatment of EH complicated with IGT. Methods A total of90 patients with EH complicated with IGT diagnosed and treated in our hospital were selected and randomly divided into the observation group(n=45, treated with conventional antihypertensive therapy combined with atorvastatin therapy) and the control group(n =45, treated with conventional antihypertensive therapy). The changes in the blood pressure, blood glucose, and blood lipid and serum inflammatory factors in the two groups were compared. Results The blood pressure(SBP and DBP) in the two groups after the treatment dropped greatly(P < 0.05), but there is no statistical difference between groups(P > 0.05); the levels of blood fat(LDL-C, TC and TG), blood glucose(2h PG), insulin resistance index(HOMA-IR) and serum inflammatory factors(IL-6 and TNF-α) in the treatment group after the treatment were much lower than those in the control group(P < 0.05). Conclusion The adjunctive treatment with atorvastatin of EH complicated with IGT can effectively relieve inflammation, lower inflammatory factors, lower blood sugar, blood fat and insulin resistance, and is worthy of popularization and application.
引文
[1]蔡冬梅,林杰,林书坡,等.高血压合并糖耐量减低患者血浆脑利钠肽水平与动脉粥样硬化的相关性[J].中国老年学杂志,2014,9:2351-2353.
[2]郭永辉,张小民.阿托伐他汀联合普罗布考对糖尿病合并高血压患者的影响[J].西北药学杂志,2015,2:191-192.
[3]王娓娓,张红苗,张雯,等.阿卡波糖对高血压伴糖耐量减低患者内皮素及C-反应蛋白的影响[J].实用医学杂志,2011,27(4):667-669.
[4]张静,白春林.高血压合并糖耐量减低患者胰岛素抵抗与C反应蛋白、肿瘤坏死因子的相关性研究[J].中西医结合心脑血管病杂志,2014,11:1326-1327.
[5]单红英,吴玉杰,刘春霞,等.高血压合并糖耐量减低患者C反应蛋白、内皮素、一氧化氮水平的变化及意义[J].中国老年学杂志,2012,32(1):52-54.
[6]葛小宁,徐吉荣,刘峰,等.阿托伐他汀对糖耐量减低原发性高血压患者血管内皮功能的影响[J].江苏医药,2012,38(18):2164-2166.
[7]单红英,张微,梁瑞景,等.每日口服10 mg阿托伐他汀对原发性高血压合并糖耐量减低患者炎症因子水平影响的临床观察[J].中国糖尿病杂志,2015,23(6):543-545.
[2]郭永辉,张小民.阿托伐他汀联合普罗布考对糖尿病合并高血压患者的影响[J].西北药学杂志,2015,2:191-192.
[3]王娓娓,张红苗,张雯,等.阿卡波糖对高血压伴糖耐量减低患者内皮素及C-反应蛋白的影响[J].实用医学杂志,2011,27(4):667-669.
[4]张静,白春林.高血压合并糖耐量减低患者胰岛素抵抗与C反应蛋白、肿瘤坏死因子的相关性研究[J].中西医结合心脑血管病杂志,2014,11:1326-1327.
[5]单红英,吴玉杰,刘春霞,等.高血压合并糖耐量减低患者C反应蛋白、内皮素、一氧化氮水平的变化及意义[J].中国老年学杂志,2012,32(1):52-54.
[6]葛小宁,徐吉荣,刘峰,等.阿托伐他汀对糖耐量减低原发性高血压患者血管内皮功能的影响[J].江苏医药,2012,38(18):2164-2166.
[7]单红英,张微,梁瑞景,等.每日口服10 mg阿托伐他汀对原发性高血压合并糖耐量减低患者炎症因子水平影响的临床观察[J].中国糖尿病杂志,2015,23(6):543-545.